GlucoTrack, Inc. Common Stock
GCTKGlucoTrack, Inc. (GCTK) is a healthcare technology company specializing in non-invasive glucose monitoring solutions. The company develops devices aimed at providing painless and convenient blood sugar measurements for individuals with diabetes. Their proprietary technology utilizes a combination of electromagnetic, thermal, and cardio signals to assess glucose levels without the need for blood samples.
Company News
Glucotrack, a medical technology company, reported strong progress in 2024, including advancing its continuous blood glucose monitoring technology from preclinical to clinical stage, strengthening its leadership team, and securing funding to support its growth plans.
Glucotrack, a medical technology company, has appointed industry veteran Peter C. Wulff as its new Chief Financial Officer. Wulff has over 35 years of financial management experience and will play a key role in the commercialization of Glucotrack's continuous blood glucose monitoring system for people with diabetes.
Diabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy
Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.
